The Supreme Court to decide on “inequitable conduct” doctrine in REGENERON PHARMACEUTICALS, INC. v.MERUS N.V

Regeneron Pharmaceuticals , Inc filed a petition for a writ of certiorari in May, 2018 seeking determination of whether the doctrine is applicable when a patentee’s trial counsel found by the lower court that allegedly committed misconduct during federal court litigation to enforce the patent right, years after the issuance of said patent.

 

 

 

About the author: sipsaslaw